Published in Lab Business Week, November 12th, 2006
The listing exception was granted based upon the company's plan to achieve compliance with NASDAQ's $35 million market value of listed securities requirement, as set forth in NASDAQ Marketplace Rule 4310(c)(2)(B).
As part of the plan of compliance, the company's largest stockholder, Durus Life Sciences Master Fund, Ltd., has indicated its willingness to convert shares of Series B preferred stock of the company into shares of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Lab Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.